Search for a trial

Inguinal or Ilio-inguinal Lymphadenectomy for Patients With Metastatic Melanoma to Groin Lymph Nodes and no Evidence of Pelvic Disease on PET/CT Scan - A Randomised Phase III Trial (EAGLE FM)

This study aims to provide a more rational evidence base for appropriate management for metastatic melanoma in the groin LNs, through assessing the effect of the addition of ipsilateral pelvic lymphadenectomy on patient disease-free survival (DFS),…

A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma

Primary objectiveTo compare the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine.Secondary objectivesEfficacy- To compare the objective response of subjects treated with either pimasertib or dacarbazine.- To…

A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.
The ReCab trial

Primary objectives:To establish a safe and effective dosing schedule for repeated administration of Rhenium-188 HEDP combined with Cabazitaxel in order to proceed with a Randomised Phase 2 trial designed to determine the clinical value of Rhenium-…

Immediate versus delayed stereotactic ablative radiotherapy (SABR) for patients with pulmonary oligometastases from colorectal cancer: SABR SCAN Trial. A randomised clinical trial

To determine the effect upon progression free survival and upon tumourload relative to baseline, both at one year after randomisation of immediate SABR versus delayed SABR (a scan-and-personalise policy). Secondarily, patterns of progression,…

Postoperative local stereotactic radiotherapy versus observation following complete resection of a single brain metastasis

To improve local control following complete resection of a single brain metastasis using fractionated local stereotactic radiotherapy, whilst maintaining neurological functioning, neurocognition and quality of life.

Randomized controlled trial comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases

Our aim is to study whether the pain response after three months in patients with bone metastatic disease increases after SBRT in comparison to low dose EBRT.

An open-label, single-arm, phase II, multicenter study to evaluate;the efficacy of vemurafenib in metastatic melanoma patients with brain metastases

The primary objective of this trial is to evaluate the efficacy of vemurafenib using BestOverall Response Rate (BORR), as assessed by an Independent Review Committee (IRC)using RECIST, v1.1 criteria in the brain of metastatic melanoma patients with…

Stereotactic ablative radiotherapy (SABR) after systemic antineoplastic treatment for patients with unresectable oligometastases (lung; liver; adrenal glands) from solid tumours:
SARASTRO Trial
(Stereotactic Ablative Radiotherapy After Systemic TReatment for Oligometastases)
A randomised phase II trial

To explore, whether the magnitude of the effect - in terms of progression free survival at one year - due to the addition of SABR after chemotherapy for selected patients with metastatic disease from solid (non-germinoma) tumours might justify a…

A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy

The primary objective of this study is to compare the overall survival (OS) of ramucirumab DP administered in combination with docetaxel versus docetaxel with placebo as therapy for patients with Stage IV non-small cell lung cancer (NSCLC) who have…

Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases form wild type KRAS colorectal cancer. EORTC 40091.

Primary objective: to detect an increase in progression free survival (PFS*, see chapter 7.3.6) rate at 1 year in each experimental arm (mFOLFOX6 + bevacizumab or panitumumab) compared to mFOLFOX6 alone arm as perioperative treatment for resectable…

Pretherapeutic para-aortic lymphadenectomy in advanced stage cervical cancer.

1. To study the safety and feasibility of para-aortic surgical staging in advanced cervical cancer in the Netherlands.2. To provide insight in the possible effectiveness of para-aortic surgical staging in advanced cervical cancer as compared to…

Effect of aminobisphosphonates and statins on circulating Vgamma9Vdelta2-T cells

To study (in patients who have an indication for treatment with an intravenous aminobisphosponate because of bone metastases of a malignant tumor) the effects of aminobisphophonate treatment on the phenotype and function on circulating Vy9Vd2-T…

An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Primary ObjectiveTo compare the objective response rate and overall surival of BMS-936558 versus docetaxel in subjects with squamous cell NSCLC after failure of prior platinum-based chemotherapySecondary ObjectivesTo compare the progression-free…

A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer

The purpose of this clinical research study is to compare the effect of panitumumab to cetuximab (Erbitux®) in treating metastatic colorectal cancer in patients whose tumor contains the wild-type (unchanged) KRAS gene and who have previously been…

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial

To assess the impact of a comprehensive oligometastatic SABR treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions, compared to patients who receive standard of care treatment alone.

A RANDOMIZED PHASE II STUDY OF CONCOMITANT TRASTUZUMAB, BEVACIZUMAB WITH PACLITAXEL VERSUS TRASTUZUMAB AND BEVACIZUMAB FOLLOWED BY THE COMBINATION OF TRASTUZUMAB, BEVACIZUMAB AND PACLITAXEL AT PROGRESSION AS FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER WITH HER2-NEU OVEREXPRESSION

Primary objective: To establish whether concomitant therapy of trastuzumab, bevacizumab with paclitaxel (regimen A) and/or trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab, and paclitaxel at progression (regimen B…

Effectiveness of postoperative radiotherapy in patients with oral or oropharyngeal squamous cell carcinoma and histologically confirmed single ipsilateral lymphnode metastasis (pN1)

To determine the optimal therapy for patients with pT1-2 pN0 oral and oropharyngeal cancer

Docetaxel versus Docetaxel and Lapatinib in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
An open label multicenter randomized phase II study.
A study of the Dutch Head and Neck Cancer Group (DHNCG)
(NWHHT 08-02)

The primary objective of this study is to select the candidate treatment with the highest level of activity for subsequent phase III testing. Activity is defined as clinical benefit (CR,PR or stable disease) in patients with recurrent SCCHN not…

Pharmacokinetics of bevacizumab in patients with malignant ascites

To study pharmacokinetics of intravenously and intraperitoneally administered bevacizumab in patients with malignant ascites for whom there is no systemic anti-tumour treatment available.

A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients
With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2: To evaluate progression-free survival (PFS) as the primary efficacy measure of MLN1117 plus docetaxel versus docetaxel alone in patients with advanced NSCLC